An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes
Yuanjin Zhang(Peking University), Benjamin F. Cravatt(Scripps Institution of Oceanography), Matthew D. Petroski(Pfizer (United States)), Zhonglin Liu(Sun Yat-sen University), Sang Joon Won(Scripps Research Institute), Oleg Brodsky(Pfizer (United States)), Todd VanArsdale(Pfizer (United States)), Asako Nagata(Pfizer (United States)), Marscha Hirschi(Pfizer (United States)), Matthew M. Hayward(Pfizer (United States)), Sherry Niessen(Pfizer (United States)), Bruno Melillo(Scripps Research Institute), Andrew R. Nager(Pfizer (United States)), Eric F. Johnson(Pfizer (United States)), A. Gilbert(Pearl River Community College), Divya Bezwada(Children's Medical Center), Al Stewart(Pfizer (United States)), Jaimeen D. Majmudar(Pfizer (United States))
Cited by 19
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
|Annual Review of Biochemistry|2008|1.3k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770